These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 34361048)
21. [Chinese guideline for clinical diagnosis and treatment of malignant pleural mesothelioma (2021 Edition)]. Multidisciplinary Committee of Oncology, Chinese Physicians Association Zhonghua Zhong Liu Za Zhi; 2021 Apr; 43(4):383-394. PubMed ID: 33902201 [TBL] [Abstract][Full Text] [Related]
22. Iron signature in asbestos-induced malignant pleural mesothelioma: A population-based autopsy study. Crovella S; Bianco AM; Vuch J; Zupin L; Moura RR; Trevisan E; Schneider M; Brollo A; Nicastro EM; Cosenzi A; Zabucchi G; Borelli V J Toxicol Environ Health A; 2016; 79(3):129-41. PubMed ID: 26818092 [TBL] [Abstract][Full Text] [Related]
23. Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas. Kang HC; Kim HK; Lee S; Mendez P; Kim JW; Woodard G; Yoon JH; Jen KY; Fang LT; Jones K; Jablons DM; Kim IJ Oncotarget; 2016 Feb; 7(7):8321-31. PubMed ID: 26824986 [TBL] [Abstract][Full Text] [Related]
24. BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival. Bahnasy AA; El-Din RS; Sabri NA; Abdel-Rahman CA; Bastawisy AE Cancer Genet; 2018 Dec; 228-229():83-92. PubMed ID: 30553477 [TBL] [Abstract][Full Text] [Related]
25. Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group. Remon J; Nadal E; Dómine M; Ruffinelli J; García Y; Pardo JC; López R; Cilleruelo A; García-Campelo R; Martín P; Juan O; González-Larriba JL; Provencio M; Olmedo E; Ponce S; Cumplido D; Barenys C; Majem M; Massutti B; Rodriguez-Abreu D; Porta R; Sala MA; Martinez-Kareaga M; Lianes P; Reguart N Lung Cancer; 2020 Sep; 147():83-90. PubMed ID: 32682189 [TBL] [Abstract][Full Text] [Related]
26. A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma. Lam WS; Creaney J; Chen FK; Chin WL; Muruganandan S; Arunachalam S; Attia MS; Read C; Murray K; Millward M; Spiro J; Chakera A; Gary Lee YC; Nowak AK Lung Cancer; 2020 Feb; 140():87-92. PubMed ID: 31901768 [TBL] [Abstract][Full Text] [Related]
28. Clinical feature of diagnostic challenging cases for pleural biopsy in patient with malignant pleural mesothelioma. Hashimoto M; Sato A; Kuroda A; Nakamura A; Nakamichi T; Kondo N; Yuki M; Nabeshima K; Tsujimura T; Hasegawa S Gen Thorac Cardiovasc Surg; 2020 Aug; 68(8):820-827. PubMed ID: 31981139 [TBL] [Abstract][Full Text] [Related]
29. Malignant Pleural Mesothelioma: State of the art and advanced cell therapy. Facchetti G; Petrella F; Spaggiari L; Rimoldi I Eur J Med Chem; 2017 Dec; 142():266-270. PubMed ID: 28800871 [TBL] [Abstract][Full Text] [Related]
30. Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma. Villanova T; Gesmundo I; Audrito V; Vitale N; Silvagno F; Musuraca C; Righi L; Libener R; Riganti C; Bironzo P; Deaglio S; Papotti M; Cai R; Sha W; Ghigo E; Schally AV; Granata R Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2226-2231. PubMed ID: 30659154 [TBL] [Abstract][Full Text] [Related]
31. The role of microRNAs in the diagnosis and treatment of malignant pleural mesothelioma--a short review. Sheff KW; Hoda MA; Dome B; Hegedus B; Klepetko W; Weiss GJ Microrna; 2012; 1(1):40-8. PubMed ID: 25048089 [TBL] [Abstract][Full Text] [Related]
32. Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications. Tolani B; Acevedo LA; Hoang NT; He B Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29342862 [TBL] [Abstract][Full Text] [Related]